Claims for Patent: RE44872

Summary for Patent: RE44872

Title:	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract:	(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.
Inventor(s):	Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Application Number:	13/542,308
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE44872
Patent Claims:	1. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof as an active ingredient, wherein the subject is not suffering from diabetes. 2. The method according to claim 1, wherein the overactive bladder is a result of benign prostatic hyperplasia. 3. The method according to claim 1, wherein the subject has urinary urgency. 4. The method according to claim 1, wherein the subject has urinary urge incontinence. 5. The method according to claim 1, wherein the subject has pollakiuria. 6. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide, in its free base form, as an active ingredient, wherein the subject is not suffering from diabetes. 7. The method according to claim 6, wherein the overactive bladder is a result of benign prostatic hyperplasia. 8. The method according to claim 6, wherein the subject has urinary urgency. 9. The method according to claim 6, wherein the subject has urinary urge incontinence. 10. The method according to claim 6, wherein the subject has pollakiuria. 11. The method according to claim 1, wherein the subject is human. 12. The method according to claim 6, wherein the subject is human. .Iadd.13. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)ami- no]ethyl]acetic acid anilide or a salt thereof as an active ingredient, wherein when the subject is not an adult, the subject is not suffering from diabetes..Iaddend. .Iadd.14. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)ami- no]ethyl]acetic acid anilide, in its free base form, as an active ingredient, wherein when the subject is not an adult, the subject is not suffering from diabetes..Iaddend.